糖尿病合并肺毛霉病1例

中国真菌学杂志　 2020, Vol. 15 　Issue (6): 371-373.

糖尿病合并肺毛霉病1例

孙凌月, 余进, 李若瑜, 王爱平

北京大学第一医院皮肤性病科, 北京大学真菌和真菌病研究中心, 皮肤病分子诊断北京市重点实验室, 国家皮肤与免疫疾病临床医学研究中心, 北京 100034

收稿日期:2020-05-12 发布日期:2020-12-28
通讯作者: 王爱平,E-mail:wangap516@163.com E-mail:wangap516@163.com
作者简介:孙凌月,女(汉族),在读博士研究生.E-mail:luna@bjmu.edu.cn

Received:2020-05-12 Published:2020-12-28

摘要/Abstract

摘要： 报道糖尿病合并肺毛霉病1例。患者，男，37岁，多尿、多饮1个月，发热、咳嗽15 d。实验室检查确诊患者有糖尿病及糖尿病酮症，同时胸部CT显示双肺上叶病变，给予降糖及抗细菌治疗，肺实变灶扩大，出现空洞、胸腔积液。经过支气管镜肺组织活检，组织病理可见大量宽大无隔的菌丝，确诊肺毛霉病。给予患者两性霉素B治疗5 d，因肾损害停用；之后口服泊沙康唑混悬液600 mg/d治疗3周，发热及咳嗽消失，患者自行停药，9个月后随访患者无不适主诉。

关键词: 肺毛霉病, 泊沙康唑, 糖尿病, 糖尿病酮症

中图分类号:

R519.8

孙凌月, 余进, 李若瑜, 王爱平. 糖尿病合并肺毛霉病1例[J]. 中国真菌学杂志, 2020, 15(6): 371-373.

参考文献

[1] Prakash H, Chakrabarti A. Global epidemiology of mucormycosis[J]. J Fungi (Basel), 2019, 5(1):E26.
[2] Pilmis B, Alanio A, Lortholary O, et al. Recent advances in the understanding and management of mucormycosis[J]. F1000Res, 2018, 7:F1000 Faculty Rev-1429.
[3] Agrawal R, Yeldandi A, Savas H,et al. Pulmonary mucormycosis:risk factors, radiologic findings, and pathologic correlation[J].Radiographics, 2020, 40(3):656-666.
[4] 冉元帅,骆望兰,肖昆,等. 肺部真菌感染CT诊断进展[J].中国真菌学杂志,2020,15(1):55-60.
[5] Hammer MM, Madan R, Hatabu H. Pulmonary mucormycosis:radiologic features at presentation and over time[J]. AJR Am J Roentgenol, 2018, 210(4):742-747.
[6] Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis[J]. Clin Infect Dis, 2012, 54(Suppl 1):S23-S34.
[7] Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis[J]. Clin Infect Dis, 2012, 54(suppl 1):S16-S22.
[8] Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis:an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis, 2019, 19(12):e405-e421.
[9] Jung J, Park YS, Sung H, et al. Using immunohistochemistry to assess the accuracy of histomorphologic diagnosis of aspergillosis and mucormycosis[J]. Clin Infect Dis, 2015, 61(11):1664-1670.
[10] Greenberg RN, Mullane K, vanBurik JA, et al. Posaconazoleas salvage therapy for zygomycosis[J]. Antimicrob Agents Chemother, 2006, 50(1):126-133.
[11] van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis:a retrospective summary of 91 cases[J]. Clin Infect Dis, 2006, 42(7):e61-e65.
[12] Yamin HS, Alastal AY, Bakri I. Pulmonary mucormycosis over 130 years:A case report and literature review[J]. Turk Thorac J, 2017, 18(1):1-5.